CORT · Corcept Therapeutics
AI read · Good for CORT
The AI's read
That case adds evidence about relacorilant's possible use in a rare cancer. The patient's disease remained stable, with no new lesions, as of July 2026. Still, one patient's experience cannot show whether other patients will respond.